Patents Examined by Albert M Navarro
-
Patent number: 11994511Abstract: Described herein are materials and methods for the treatment of prostate cancer.Type: GrantFiled: April 4, 2018Date of Patent: May 28, 2024Assignee: UNIVERSITY OF MIAMIInventors: Kerry L. Burnstein, Fiorella Magani
-
Patent number: 11986519Abstract: Provided herein are Haemophilus influenzae saccharide-carrier conjugates and compositions thereof. Also provided are methods of making and using the conjugates and compositions thereof, and kits containing the conjugates. Haemophilus influenzae saccharide-lipid conjugates, Haemophilus influenzae saccharide-glycosphingolipid conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed. Saccharide-lipid conjugates, and saccharide-glycosphingolipid conjugates comprising saccharides from Haemophilus influenzae serotype a, as well as compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed.Type: GrantFiled: January 5, 2022Date of Patent: May 21, 2024Inventor: Eva Barbara Schadeck
-
Patent number: 11986535Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof (Fig. 6b).Type: GrantFiled: June 13, 2022Date of Patent: May 21, 2024Assignee: NBE THERAPEUTICS AGInventors: Ulf Grawunder, Roger Renzo Beerli
-
Patent number: 11975060Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.Type: GrantFiled: January 18, 2021Date of Patent: May 7, 2024Assignee: The Texas A&M University SystemInventors: Thomas A. Ficht, Allison Ficht, Renee Tsolis, Leslie Garry Adams, Angela M. Arenas-Gamboa
-
Patent number: 11976097Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.Type: GrantFiled: October 13, 2022Date of Patent: May 7, 2024Assignee: Children's Medical Center CorporationInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Patent number: 11970728Abstract: The present application discloses a method for rapidly identifying the resistance of wheat to black point disease caused by Bipolaris sorokiniana, where testing takes places in an indoor, controlled environment. The test method includes surface sterilization of wheat seeds, and cultivating wheat seedlings from the sterilized wheat seeds; preparing conidial suspension of Bipolaris sorokiniana, and spraying the conidial suspension on the seedlings at one-leaf-one-shoot stage; recording the percentage of the diseased leaf area in total leaf area of the first leaf of the wheat seedling on the 10th day of inoculation; calculating the black point incidence of the wheat according to an equation, and then evaluating the resistance of wheat to black point disease caused by Bipolaris sorokiniana through the black point incidence.Type: GrantFiled: April 16, 2021Date of Patent: April 30, 2024Assignee: Henan Agricultural UniversityInventors: Qiaoyun Li, Guihong Yin, Haiyong Li, Yumei Jiang, Jishan Niu, Mengyu Li, Siyu Wang, Kaige Xu
-
Patent number: 11965875Abstract: The present application relates to a system and a method for effectively screening and assessing agents for tumor immunotherapy, which includes assessment for the effects of target cells, non-target cells, and tumor infiltration. The system and method of the present application can be used to comprehensively and systematically assess the effectiveness and safety of the agent against tumor immune cells.Type: GrantFiled: May 18, 2021Date of Patent: April 23, 2024Assignee: ADLAI NORTYE BIOPHARMA CO. LTD.Inventors: Nanhai He, Youping Wang, Yang Lu, Donghui Yang
-
Patent number: 11965888Abstract: Disclosed herein are methods for quantifying total endotoxin load in a biofilm sample. Also provided are methods for identifying a gram-negative biofilm derived bacterial infection. The disclosed methods more accurately define actual total endotoxin levels and can detect the presence of endotoxin in a given biofilm volume at a higher resolution than current extraction techniques.Type: GrantFiled: April 6, 2021Date of Patent: April 23, 2024Assignee: DePuy Synthes Products, Inc.Inventors: Erica Shwarz, Wojciech Czaja
-
Patent number: 11957744Abstract: The present invention discloses a vaccine formulation in accordance with an illustrative embodiment. The formulation including a live attenuated cholera vaccine strain VCUSM14P; a vaccine medium having starch, cellulose, dextrose, and yeast extract; and a phosphate buffer saline.Type: GrantFiled: December 26, 2018Date of Patent: April 16, 2024Assignee: AIMST UNIVERSITYInventors: Guruswamy Prabhakaran, Manickam Ravichandran, Kurunathan A/L Sinniah, Yean Yean Chan
-
Patent number: 11933781Abstract: A method of screening a test compound, e.g., a fibrosis or IPF inhibitor, for induction of an unjammed-to-jammed transition (UJT) in fibrotic primary human bronchial epithelial cells (HBECs) isolated from a subject with a fibrotic lung disease includes culturing the fibrotic primary HBECs at an air-liquid interface for a time sufficient to provide a differentiated pseudostratified epithelium contacting the cultured cells with the test compound; and monitoring the motility of the cultured cells to identify the cultured cells as moving or stationary; wherein stationary cultured cells indicate that the test compound induces the UJT. Also included are methods of identifying lung fibrosis biomarkers.Type: GrantFiled: December 9, 2021Date of Patent: March 19, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: David Schwartz, Ian Stancil
-
Patent number: 11926853Abstract: Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.Type: GrantFiled: December 17, 2019Date of Patent: March 12, 2024Assignee: The Research Foundation For Microbial Diseases of Osaka UniversityInventors: Daisuke Yokouchi, Akiko Miura, Ryu Okada, Yuzo Yamashita, Yuya Sasaki, Shogo Nishihata
-
Patent number: 11912769Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.Type: GrantFiled: January 25, 2022Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
-
Patent number: 11913954Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.Type: GrantFiled: February 8, 2021Date of Patent: February 27, 2024Assignee: Bio-Rad Laboratories, Inc.Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
-
Patent number: 11911764Abstract: The invention provides novel sample chambers, sample analysis units, multi-well plates, and imaging and analytical systems as well as methods for accurate, efficient and high-throughput imaging, measurement and analysis of diverse types of biological cells to obtain information such as cell count, cell size, cell concentration, cell sub-population, cell morphology, cell viability, etc.Type: GrantFiled: February 21, 2019Date of Patent: February 27, 2024Assignee: Nexcelom Bioscience LLCInventors: Peter Y. Li, Jean Qiu, Leo L. Chan, Justin R. Hascup, Timothy F. Smith, Todd R. Sobolewski, Nicholas N. Shaw
-
Patent number: 11911452Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: September 10, 2021Date of Patent: February 27, 2024Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
-
Patent number: 11903982Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.Type: GrantFiled: May 10, 2022Date of Patent: February 20, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANCAIS DU SANG (EFS), UNIVERSITE DE BRETAGNE OCCIDENTALE, CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BRESTInventors: Rozenn Le Berre, Marie-Sarah Fangous, Gwenaelle Le Blay, Geneviève Hery-Arnaud, Rosyne Lagrafeuille
-
Patent number: 11903388Abstract: Described herein are methods for obtaining useful compounds from lichens.Type: GrantFiled: December 17, 2021Date of Patent: February 20, 2024Assignee: Board of Trustees of Michigan State UniversityInventors: Frances Trail, Ludmila Roze, John E. Linz
-
Patent number: 11906497Abstract: The invention relates to methods and devices for quantitative determination of bacteria.Type: GrantFiled: September 28, 2020Date of Patent: February 20, 2024Assignee: Swiss Analyze Bacteria AGInventors: Dieter Ebert, Mathias Reichl, Werner Lubitz
-
Patent number: 11896656Abstract: A method is described for reconstituting lyophilized mutant diphtheria toxin in dimethyl sulfoxide for use in producing pneumococcal capsular polysaccharide mutant diphtheria toxin conjugates.Type: GrantFiled: April 25, 2019Date of Patent: February 13, 2024Assignee: MERCK SHARP & DOHME LLCInventors: Patrick Leonard Ahl, Akhilesh Bhambhani, Christopher Jon Farrell, Patrick McHugh, Morrisa C. Jones, Daniel D. Roth, Jessica R. Sinacola, Justin Stanbro, Matthew P. Watson, Emily Wen, Michael A. Winters
-
Patent number: 11896631Abstract: The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.Type: GrantFiled: December 15, 2017Date of Patent: February 13, 2024Assignee: ALFASIGMA S.P.A.Inventors: Andrea Biffi, Walter Fiore, Ruggero Rossi